SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors digest a massive 27 billion dollar AI infrastructure deal with Meta, paired with analyst price target hikes and ongoing support from Nvidia. While some market participants are expressing concerns over share dilution and debt financing, the broader community remains heavily focused on the company's rapid scaling and its positioning as a key player in the AI compute sector.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is currently trending as investors weigh recent progress on a Nuclear Regulatory Commission materials license for its subsidiary against anticipation for the upcoming earnings report. The community remains divided, with some bulls highlighting the potential for nuclear energy to meet AI-driven power demand, while others express concerns over the company's pre-revenue status and recent insider share activity.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is surging toward all-time highs as investors position themselves ahead of a highly anticipated earnings report, fueled by reports of an HBM4 supply deal for Nvidia's new Vera Rubin systems. The community is actively debating whether the stock's massive rally is sustainable or if it represents a 'priced-in' event, with many bulls pointing to structural memory shortages and institutional accumulation as drivers for further growth toward the $500$600 range.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is experiencing significant retail momentum fueled by strong interest in its AI-driven real estate platform and optimism surrounding housing affordability legislation. Shareholders are actively debating the potential for a short squeeze, balancing excitement over the company's long-term transformation against concerns about broader market volatility and geopolitical pressures.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors digest long-term clinical data, potential buyout speculation, and strategic marketing shifts following a period of suppressed share price action. The community is actively debating the company's valuation as a standalone commercial growth story versus its viability as a takeover candidate, while maintaining a strong focus on the competitive performance of Briumvi in the MS market.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is facing significant volatility ahead of its earnings release, with investors debating whether the stock's recent pullback is a buying opportunity or a reaction to shifting market sentiment toward optical connectivity. Community discussion is sharply divided between those pointing to robust revenue growth and essential data center infrastructure demand, and others concerned about aggressive institutional selling and perceived technical weakness.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently trading in a tight consolidation range as investors monitor the company's progress on its Neutron rocket and backlog conversion, while anticipation builds for a broader industry re-rating tied to the upcoming SpaceX IPO. The community remains focused on the firm's expanding defense contracts and frequent launch cadence, often comparing it to a space-based "Uber" that serves as a key player in satellite deployment and national security.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following a significant $3 million insider purchase by Paul Manning, which has revitalized investor confidence despite recent volatility and capital raising efforts. The community remains hyper-focused on the company's upcoming Phase 3 prostate cancer trial results and the strategic potential for a multi-billion dollar buyout as the firm moves toward a planned BLA submission.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is currently a focal point for investors due to extreme volatility driven by a high short interest, with many in the community speculating on a potential short squeeze. Sentiment is split between those viewing the company's AI-driven mortgage automation as a transformative industry disruptor and others wary of the stock's significant price decline and ongoing insider selling.

Elbit Systems Ltd. engages in the defense and homeland security sector. It develops and supplies airborne, land and naval systems and products for defense, homeland security, and commercial applications. The firm also provides training and support services. The company was founded in 1996 and is headquartered in Haifa, Israel.

Elbit Systems Ltd.

Elbit Systems is capturing investor attention following its recent announcement of strong financial results, including an 11% year-over-year revenue increase. The community remains actively focused on the firm's robust contract pipeline and its strategic role in modern defense technology, despite ongoing debates regarding current valuation levels and geopolitical sensitivity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ally Bridge Group NY LLC Takes $1.55 Million Position in Whitehawk Therapeutics, Inc. $WHWK

Ally Bridge Group NY LLC acquired a new stake in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities...

2,849,402 Shares in Whitehawk Therapeutics, Inc. $WHWK Purchased by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC acquired a new position in shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Free Report) in the 3rd quarter, according to its most recent 13F filing with the...

Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent...

Insider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) CEO Sells 5,100 Shares of Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) CEO David James Lennon sold 5,100 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price...

David James Lennon Sells 5,100 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) CEO David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock in a transaction that occurred on Monday, March 2nd. The shares...

Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027

Whitehawk Therapeutics CEO Dave Lennon outlined the company's strategy and near-term milestones at the Inaugural Life Sciences Conference in Miami, describing a three-program antibody-drug conjugate...

Aadi Bioscience Conference: Whitehawk CEO Details 3-Program ADC Pipeline, First Data Seen in 2027

Whitehawk Therapeutics CEO Dave Lennon presented at TD Cowen's 46th Annual Healthcare Conference, outlining the company's strategy to develop a portfolio of next-generation antibody-drug conjugates...

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences Whitehawk Therapeutics to Participate in Upcoming Investor Conferences PR Newswire MORRISTOWN, N.J., Feb. 26, 2026 MORRISTOWN...

Aadi Bioscience Conference: CEO Spotlights Whitehawk ADC Pipeline, Cash Runway Through 2028

Whitehawk Therapeutics CEO Dave Lennon outlined the company's antibody-drug conjugate (ADC) strategy and pipeline during an Annual Healthcare Conference presentation, highlighting two clinical-stage...

Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?

TEM heads into Q4 earnings with expected 82.8% revenue growth, rising oncology momentum and a premium valuation clouding near-term upside.

Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Morristown, NJ.

WHWK
Whitehawk Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest WHWK News

WHWKWhitehawk Therapeutics Inc.